Core Insights - Inotiv, Inc. (NOTV) shares surged over 23% in after-hours trading following the release of preliminary fiscal fourth quarter and full year results for the period ending September 30, 2025 [1] Financial Performance - Q4 2025 revenue is projected to be between $137.5 million and $138.5 million, marking a year-over-year increase of approximately 6% from $130.4 million in Q4 2024 [1][2] - For the full fiscal year 2025, revenue is expected to be between $512.5 million and $513.5 million, reflecting a 4.5% growth compared to $490.7 million in fiscal 2024 [2] - The Discovery and Safety Assessment (DSA) services experienced significant growth, increasing by 60% year-over-year in Q4 [2] Operational Metrics - The company reported a book-to-bill ratio of approximately 1.08x for Q4 and 1.05x for FY2025, with a backlog of $138 million at the end of September 2025 [2] - CEO Robert Leasure Jr. emphasized the company's progress towards financial goals set during the May investor day, highlighting sequential growth in contract awards and enhanced revenue visibility [3] Upcoming Events - Inotiv is scheduled to present at the Jefferies Global Healthcare Conference in London on November 18, 2025, where further updates are anticipated [3] - Final audited results for Q4 and FY2025 will be reported in early December [3] Stock Performance - Over the past year, NOTV shares have traded between $0.65 and $6.48, closing at $0.68 before rising to $0.84 in after-hours trading, reflecting a 23.53% increase [4]